Resolution of chronic inflammation and cancer
- PMID: 39177291
- DOI: 10.1111/prd.12603
Resolution of chronic inflammation and cancer
Abstract
Chronic inflammation poses challenges to effective cancer treatment. Although anti-inflammatory therapies have shown short-term benefits, their long-term implications may be unfavorable because they fail to initiate the necessary inflammatory responses. Recent research underscores the promise of specialized pro-resolving mediators, which play a role in modulating the cancer microenvironment by promoting the resolution of initiated inflammatory processes and restoring tissue hemostasis. This review addresses current insights into how inflammation contributes to cancer pathogenesis and explores recent strategies to resolve inflammation associated with cancer.
Keywords: cancer; chronic inflammation; resolution; specialized pro‐resolving mediators.
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Hou J, Karin M, Sun B. Targeting cancer‐promoting inflammation ‐ have anti‐inflammatory therapies come of age? Nat Rev Clin Oncol. 2021;18(5):261‐279. doi:10.1038/s41571-020-00459-9
-
- Virchow R. Cellular Pathology as Based upon Physiological and Pathological Histology. August Hirschwald; 1858.
-
- Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539‐545. doi:10.1016/S0140-6736(00)04046-0
-
- Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605‐1621. doi:10.1016/j.bcp.2006.06.029
-
- Rayburn ER, Ezell SJ, Zhang R. Anti‐inflammatory agents for cancer therapy. Mol Cell Pharmacol. 2009;1(1):29‐43. doi:10.4255/mcpharmacol.09.05